Impact of Plyometric Training Methods on Athletic Performance and Detraining Processes in Youth Female Soccer Players

July 10, 2026 updated by: Fatih GUR, Pamukkale University
Lower extremity strength, explosive power, dynamic balance, and functional range of motion are critical determinants of athletic performance and injury prevention in soccer (football). While plyometric training is widely used to improve these qualities, the comparative effects of bodyweight plyometric training versus externally loaded plyometric training, and the maintenance of these effects during detraining periods, remain unclear. This study aims to investigate the effects of two different plyometric training methods on athletic performance and subsequent detraining processes in young female soccer players. Participants will be randomly assigned to three groups: Bodyweight Plyometric Training Group (BW-PT), External Loading Plyometric Training Group (EL-PT, who will wear vests weighing 10% of their body weight), and Control Group (CG, who will only continue with routine soccer training). Training interventions will be conducted for 6 weeks, immediately followed by a 4-week detraining period. To comprehensively assess athletic performance, the following measurements will be taken at baseline (pre-test), immediately after the training period (post-test), and after the detraining period (maintenance test): Isokinetic muscle strength of knee extensors and flexors (peak torque and force development rate at 60°/s and 120°/s), Jumping performance (standing long jump, vertical jump height, and 15-second repeated jump test), Functional range of motion (via Functional Movement Screen - FMS), Dynamic balance (via Y-Balance Test). The primary objective is to determine which plyometric loading strategy, compared to traditional soccer training, provides superior and longer-lasting physiological and biomechanical adaptations in young female athletes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
    • Denizli
      • Denizli, Denizli, Turkey (Türkiye), 20160
        • Pamukkale University, Faculty of Sport Sciences
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • No history of surgery due to musculoskeletal injuries within the past 6 months.
  • No use of ergogenic supplements within the past 3 months.
  • Regular participation in routine team training sessions for at least 2 months prior to the study.

Exclusion Criteria:

  • History of any recent injury requiring a recovery period of more than one week.
  • Use of ergogenic aids or nutritional supplements during the intervention period.
  • Missing two consecutive or four non-consecutive training sessions during the study period.
  • Participation in additional structured physical training or exercises outside of the routine team practices and the study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Body-Weight Plyometric Training Group
Participants in this group will perform plyometric training using only their own body weight.
Other: Body-Weight Plyometrics
A structured plyometric training program performed twice a week for six weeks. Exercises include various jumps and bounds using only the participant's body weight. Each session lasts approximately 30 minutes.
Experimental: Plyometric Training Group With Additional Load
Participants in this group will perform plyometric training while wearing a weighted vest equal to 10% of their body weight.
Other: Additional Loaded Plyometric
A structured plyometric training program performed twice a week for six weeks. Participants will wear a weighted vest equivalent to 10% of their body weight during the exercises. Each session lasts approximately 30 minutes.
Active Comparator: Control Group
Participants in this group will continue their routine football training without any additional plyometric exercises.
Other: Routine Football Training
Participants in this group will continue to perform their standard, routine football training sessions. They will not receive any additional or structured plyometric training program during the intervention period.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Absolute Peak Torque (APT) of Knee Extensors and Flexors
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Concentric isokinetic absolute peak torque (APT) of the knee extensors and flexors (dominant leg) will be evaluated at 60°/s and 120°/s angular velocities using a Cybex Humac Norm dynamometer during 5 maximal repetitions. (Unit of measure: Nm)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Relative Peak Torque (RPT) of Knee Extensors and Flexors
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Concentric isokinetic relative peak torque (RPT) of the knee extensors and flexors (dominant leg) will be evaluated at 60°/s and 120°/s angular velocities using a Cybex Humac Norm dynamometer during 5 maximal repetitions. (Unit of measure: Nm/kg)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Time to Peak Torque (TPT) of Knee Extensors and Flexors
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Concentric isokinetic time to peak torque (TPT) of the knee extensors and flexors (dominant leg) will be evaluated at 60°/s and 120°/s angular velocities using a Cybex Humac Norm dynamometer during 5 maximal repetitions. (Unit of measure: milliseconds)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Average Peak Torque (AvPT) of Knee Extensors and Flexors
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Concentric isokinetic average peak torque (AvPT) of the knee extensors and flexors (dominant leg) will be evaluated at 60°/s and 120°/s angular velocities using a Cybex Humac Norm dynamometer during 5 maximal repetitions. (Unit of measure: Nm)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Average Rate of Force Development (AvRFD) of Knee Extensors and Flexors
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Concentric isokinetic average rate of force development (AvRFD) of the knee extensors and flexors (dominant leg) will be evaluated at 60°/s and 120°/s angular velocities using a Cybex Humac Norm dynamometer during 5 maximal repetitions. (Unit of measure: Nm/s)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Vertical Jump Height (VJH)
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Vertical jump height calculated from flight time will be evaluated using an electronic contact mat system (Fusion SmartJump, Fusion Sport, Australia). Participants will perform a countermovement jump without arm swing. The best value from 3 repetitions, separated by 1-minute rest intervals, will be recorded. (Unit of measure: cm)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Standing Long Jump (SLJ) Distance
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Horizontal jump distance will be assessed. Participants will perform a maximum distance jump with two feet from behind a starting line. The best value from 3 repetitions will be recorded. (Unit of measure: cm)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
15-Second Repeated Jump Test: Average Power (RJ15s-AP)
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Average power (RJ15s-AP) will be evaluated during 15 seconds of continuous maximal vertical jumps using an electronic contact mat system (Fusion SmartJump, Fusion Sport, Australia). Participants will jump with hands on hips and an upright trunk. The value is calculated using the Bosco equation. (Unit of Measure: W)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
15-Second Repeated Jump Test: Flight Time (RJ15s-FT)
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Flight time (RJ15s-FT) will be evaluated during 15 seconds of continuous maximal vertical jumps using an electronic contact mat system (Fusion SmartJump, Fusion Sport, Australia). Participants will jump with hands on hips and an upright trunk. The value is calculated using the Bosco equation. (Unit of Measure: ms)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
15-Second Repeated Jump Test: Number of Jumps (N-RJ15s)
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
The number of jumps (N-RJ15s) will be evaluated during 15 seconds of continuous maximal vertical jumps using an electronic contact mat system (Fusion SmartJump, Fusion Sport, Australia). Participants will jump with hands on hips and an upright trunk. (Unit of Measure: Count)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Functional Movement Capacity
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Functional movement capacity and potential asymmetries will be evaluated using the Functional Movement Screen (FMS) kit, which consists of 7 movement patterns scored from 0 to 3 (max total score: 21). (Unit of measure: Score on a scale from 0 to 21)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Dynamic Balance and Neuromuscular Control
Time Frame: Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).
Dynamic balance will be measured using the Y-Balance Test kit. Reach distances in three directions will be normalized to the participant's leg length to assess lower extremity neuromuscular control and asymmetry. (Unit of measure: Percentage)
Baseline (Week 0), immediately post-training (Week 6), and after the detraining period (2nd and 4th week).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Pamukkale University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: GUR, Pamukkale University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 20, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 19, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 19, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 2, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 10, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 15, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 15, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 10, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E-60116787-020-811428
  • 2026TAP009 (Other Grant/Funding Number: Pamukkale University Scientific Research Projects Coordination Unit)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared. The informed consent obtained from the participants does not include provisions for public data sharing. Furthermore, preserving the privacy and complete anonymization of the participants in this small, cohort-specific sports science study is a priority, which restricts the feasibility of sharing individual-level data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings